Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech urges shareholders to vote 'FOR' all four incumbent board members at the upcoming 2024 Annual Meeting. The company highlights that leading proxy advisors ISS and Glass Lewis recommended against giving control to the dissident nominees, citing their lack of a detailed plan. The Activist Group seeks to reimburse themselves over $5 million in litigation expenses from failed takeover attempts without shareholder vote.
AIM defends its clinical development strategy of partnering with institutions like AstraZeneca and Merck, emphasizing that this approach preserves cash and reduces trial risks while maintaining Ampligen rights. The company criticizes the activist nominees' backgrounds, particularly highlighting concerns about Robert Chioini's past management issues and Todd Deutsch's connections.
AIM ImmunoTech (NYSE American: AIM) has secured Patent No. 2,032,813 from the Netherlands Patent Office for its drug Ampligen (rintatolimod) to treat post-COVID fatigue. The patent was granted to CEO Thomas K. Equels and Medical Officer David R. Strayer, who assigned it to the company.
Ampligen, an RNA product candidate designed to modulate the immune system, has shown broad-spectrum antiviral effects through stimulating innate immune response. The company recently reported positive topline results from its Phase 2 study (AMP-518) evaluating Ampligen's efficacy and safety in treating post-COVID fatigue. The drug was generally well-tolerated and showed preliminary evidence of reducing fatigue in subjects with post-COVID conditions.
Based on these results, AIM plans to conduct a follow-up clinical trial focusing on moderate-to-severe post-COVID fatigue patients.
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the company's Consulting Medical Officer and founder of the Hunter-Hopkins Center. The segment focuses on the results from AIM's Phase 2 study of Ampligen® for Post-COVID fatigue condition (AMP-518). Dr. Lapp, a Key Opinion Leader with over 25 years of experience treating Chronic Fatigue Syndrome and Fibromyalgia, discusses the study's findings regarding efficacy and safety.
ISS has recommended AIM ImmunoTech shareholders vote FOR Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting.
ISS found the Activist Group's plan , with only one nominee having relevant life sciences expertise, and highlighted concerns about nominee Robert L. Chioini's track record and connections to securities law felons, recommending against his and nominee Todd A. Deutsch's election.
AIM highlighted a $15 million+ investment partnership between activist nominees Ted Kellner and Paul Sweeney, questioning their independence. The Company urged shareholders to vote for all four incumbent candidates on the WHITE proxy card.
Dr. William M. Mitchell emphasized the Company's ability to secure funding for clinical trials and the expertise of the Board members, particularly Tom Equels and Stewart Appelrouth. AIM remains focused on high-value indications like pancreatic cancer to create long-term value.
AIM ImmunoTech has issued a presentation urging shareholders to vote against four director candidates nominated by an activist investor group at the upcoming 2024 Annual Meeting. The company highlights serious concerns about the nominees: Robert Chioini was previously fired for mismanagement, Todd Deutsch has connections to individuals involved in securities fraud, Ted Kellner was found by court to have provided false information to shareholders, and Paul Sweeney lacks independence due to extensive business ties with Kellner.
The activist group is seeking over $5 million in reimbursement for failed litigation expenses, plus additional proxy contest costs, without shareholder approval.
AIM ImmunoTech has issued a statement refuting claims made by an activist investor group regarding their attempt to take control of the company's Board of Directors at the upcoming 2024 Annual Meeting. The company specifically addresses the activist group's false claim about AIM's historical share price, stating that contrary to the group's assertion of $87.15 on February 25, 2016, the stock was actually trading at $0.16 as of March 15, 2016.
The Delaware Court of Chancery has previously found that the activist group made multiple misleading statements and omissions in their 2022 and 2023 nomination notices. The company urges shareholders to vote 'FOR' all four incumbent Board candidates.
AIM ImmunoTech has announced a cash conservation plan to maintain momentum in achieving clinical milestones. Independent directors will receive 100% of their compensation in company stock instead of cash. Previously disclosed amendments to executive employment agreements reduce cash salaries by $200,000 for CEO Thomas Equels and $50,000 for COO Peter Rodino, replacing these amounts with stock compensation. Notably, CEO Equels purchased 361,458 company shares between November 2023 and November 2024. The Board emphasizes its belief in Ampligen's potential to address unmet medical needs and create shareholder value through commercialization.
AIM ImmunoTech (NYSE American: AIM) has issued a presentation defending its current board members ahead of its 2024 Annual Meeting. The company highlights its clinical development progress, particularly in pancreatic cancer, and ongoing partnerships with AstraZeneca and Merck. The presentation warns against an Activist Group seeking board control, noting their demand for over $5 million in reimbursement for previous litigation costs. The company reveals that despite settlement attempts, the Activist Group demanded up to $8 million, representing over 50% of AIM's market cap. The board urges shareholders to vote for incumbent candidates and reject the Activist Group's proposals.
The Kellner Group, AIM Immunotech's largest stockholder, urges shareholders to vote using the GOLD proxy card to elect new board members, citing serious concerns about the incumbent board's conduct. The Delaware Supreme Court ruled that the board breached its fiduciary duties by adopting inequitable bylaws to maintain control. The group estimates the board spent $15-20 million in litigation to prevent meaningful director elections, contributing to a 99+% stock price decline. The Kellner Group nominees - Ted Kellner, Todd Deutsch, Robert Chioini, and Paul Sweeney - promise to bring needed change to address increasing losses, excessive spending, and poor governance.
AIM ImmunoTech announced the publication of data from Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating Ampligen® as part of a chemokine-modulating regimen in early-stage triple-negative breast cancer (TNBC). The study results, published in The Journal for ImmunoTherapy of Cancer, showed that the Ampligen-containing regimen can modify the tumor microenvironment and release cytokines that attract killer T-cells into early-stage TNBC tumors. Study principal investigator Dr. Shipra Gandhi noted the promising results while emphasizing the need for validation in a larger study.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
